Actividad antibacteriana del péptido LfcinB (20-25)4 contra aislados clínicos multirresistentes de E. coli Y S. aureus

Vista sencilla de ítem
dc.contributor.advisorRivera Monroy, Zuly Jenny
dc.contributor.advisorParra Giraldo, Claudia Marcela
dc.contributor.authorBonilla Velásquez, Laura Daniela
dc.contributor.researchgroupSíntesis y aplicación de moléculas peptídicasspa
dc.date.accessioned2021-08-20T15:36:37Z
dc.date.available2021-08-20T15:36:37Z
dc.date.issued2021-05-30
dc.descriptionTexto
dc.descriptionilustraciones, gráficas, tablasspa
dc.description.abstractLos péptidos antimicrobianos (PAMs) constituyen una alternativa terapéutica para el desarrollo de tratamientos de enfermedades infecciosas, que podrían contrarrestar el ascendente número de microorganismos resistentes a antibióticos que han incrementado el problema de salud pública a nivel mundial. La OMS en el año 2018, reportó la aparición de cepas resistentes y multirresistentes, bacterias como Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii y Staphylococcus aureus, han desarrollado mecanismos de resistencia frente a los antibióticos de primera línea, evidenciando la ineficacia de los fármacos utilizados comúnmente. Como una estrategia para ampliar las alternativas terapéuticas los péptidos derivados de la Lactoferricina Bovina (LfcinB), que contienen el motivo mínimo de actividad antimicrobiana RRWQWR, han sido evaluados contra cepas de referencia Gram positivas y Gram negativas, esta investigación ha permitido enfocar el péptido tetramérico LfcinB (20-25)4 con actividad antibacteriana promisoria. Dando continuidad a esta investigación, en el presente trabajo se evaluó la actividad antibacteriana de LfcinB (20-25)4 contra aislados clínicos de S. aureus y E. coli los cuales presentan diferentes perfiles de resistencia. Se determinó que el péptido tetramérico presenta actividad contra los aislados clínicos evaluados, con Concentraciones Mínimas Inhibitorias (CMI) en el rango de 11 μM a 22 μM para bacterias Gram positivas y 5 μM a 22 μM para Gram negativas; estos resultados muestran que este péptido LfcinB (20-25)4 con actividad antibacteriana, tanto en cepas de referencia como en aislados clínicos, es una alternativa viable para el desarrollo de nuevos agentes terapéuticos. (Texto tomado de la fuente)spa
dc.description.abstractAntimicrobial peptides (PAMs) are an alternative to the development of new antibacterial therapies, which could counteract the ascending number of antibiotic- resistant microorganisms that have increased the global public health problem. In the latest WHO reports in 2018, it indicates that bacteria such as Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus, exhibit resistance against first-line antibiotics and are classified as resistant and multidrug-resistant strains, demonstrating the inefficiency of drugs worldwide. Within this context, peptides derived from Lactoferricin Bovina (LfcinB) containing the minimum motif, have been evaluated against Gram-positive and Gram-negative reference strains. In this work, the tetrameric peptide LfcinB (20- 25)4 was evaluated against clinical isolates of S. aureus and E. coli that have been classified as multidrug-resistant by the Institute of Cancerology of Bogota, with a new identification through MALDI TOF. The activity of this peptide was demonstrated against the clinical isolates evaluated, having a minimal inhibitory concentration (MIC) within the range of 11 – 22μM for Gram-positive bacteria and 5 – 22μM for Gram negatives. In addition, the activity in combination with ciprofloxacin was evaluated for one of the isolates with higher percentages of antibiotic resistance, resulting in an additive effect that maintained the concentration of the peptide. All these results show that the tetrameric peptide LfcinB (20-25)4 with antibacterial activity, is a viable alternative for the development of new therapeutic agents. (Text taken from source)eng
dc.description.degreelevelMaestríaspa
dc.description.degreenameMagíster en Ciencias - Microbiologíaspa
dc.description.researchareaMicrobiologíaspa
dc.format.extent93 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.identifier.instnameUniversidad Nacional de Colombiaspa
dc.identifier.reponameRepositorio Institucional Universidad Nacional de Colombiaspa
dc.identifier.repourlhttps://repositorio.unal.edu.co/spa
dc.identifier.urihttps://repositorio.unal.edu.co/handle/unal/79982
dc.language.isospaspa
dc.publisherUniversidad Nacional de Colombiaspa
dc.publisher.branchUniversidad Nacional de Colombia - Sede Bogotáspa
dc.publisher.departmentInstituto de Biotecnología (IBUN)spa
dc.publisher.facultyFacultad de Cienciasspa
dc.publisher.placeBogotá, Colombiaspa
dc.publisher.programBogotá - Ciencias - Maestría en Ciencias - Microbiologíaspa
dc.relation.referencesInoue H, Minghui R. Antimicrobial resistance: Translating political commitment into national action. Bull World Health Organ. 2017;95(4):242- 242A.spa
dc.relation.referencesShrivastava SR, Shrivastava PS, Ramasamy J. World health organization releases global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. JMS - J Med Soc. 2018;32(1):76–7.spa
dc.relation.referencesExner M, Bhattacharya S, Christiansen B, Gebel J, Goroncy-Bermes P, Hartemann P, et al. Antibiotic resistance: What is so special about multidrug- resistant Gram-negative bacteria? GMS Hyg Infect Control [Internet]. 2017;12:Doc05. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28451516%0Ahttp://www.pubmedce ntral.nih.gov/articlerender.fcgi?artid=PMC5388835spa
dc.relation.referencesWillyard C. The drug-resistant bacteria that pose the greatest health threats. Nature. 2017;543(7643):15.spa
dc.relation.referencesAminov RI. A brief history of the antibiotic era: Lessons learned and challenges for the future. Front Microbiol. 2010;1(DEC):1–7.spa
dc.relation.referencesBlair JMA, Webber MA, Baylay AJ, Ogbolu DO, Piddock LJV. Molecular mechanisms of antibiotic resistance. Nat Rev Microbiol [Internet]. 2015;13(1):42–51. Available from: http://dx.doi.org/10.1038/nrmicro3380spa
dc.relation.referencesOMS. Resistencia a los antimicrobianos Situación actual Resistencia de las bacterias [Internet]. 2020. Available from: https://www.who.int/es/news- room/fact-sheets/detail/resistencia-a-los-antimicrobianosspa
dc.relation.referencesGrupo de Microbiología Subdirección Laboratorio Nacional de Referencia (SLNR). Infecciones asociadas a la atención en salud. Epidemiología de las infecciones asociadas a la atención en salud. 2019.spa
dc.relation.referencesMinisterio de Salud y Protección Social. Plan Nacional de Respuesta a la Resistencia a los Antimicrobianos - plan estratégico. 2018;66. Available from: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/MET /plan-respuesta-resistencia-antimicrobianos.pdfspa
dc.relation.referencesMaldonado NA, Múnera MI, López JA, Sierra P, Robledo C, Robledo J, et al. Tendencias de la resistencia a antibióticos en Medellín y en los municipios del área metropolitana entre 2007 y 2012: Resultados de seis años de vigilancia. Biomedica. 2014;34(3):433–46.spa
dc.relation.referencesChung PY, Khanum R. Antimicrobial peptides as potential anti-biofilm agents against multidrug-resistant bacteria. J Microbiol Immunol Infect [Internet]. 2017;50(4):405–10. Available from: http://dx.doi.org/10.1016/j.jmii.2016.12.005spa
dc.relation.referencesBahar AA, Ren D. Antimicrobial peptides. Pharmaceuticals. 2013;6(12):1543– 75.spa
dc.relation.referencesRodríguez-Franco DA, Vázquez-Moreno L, Ramos-Clamont Montfort G. Actividad antimicrobiana de la lactoferrina: Mecanismos y aplicaciones clínicas potenciales. Rev Latinoam Microbiol. 2005;47(3–4):102–11.spa
dc.relation.referencesMurata M, Wakabayashi H, Yamauchi K, Abe F. Identification of milk proteins enhancing the antimicrobial activity of lactoferrin and lactoferricin. J Dairy Sci [Internet]. 2013;96(8):4891–8. Available from: http://dx.doi.org/10.3168/jds.2013-6612spa
dc.relation.referencesL.Cheng-Foh FM, S.Shamala. Intracellular Targeting Mechanisms by antimicrobial peptides. 2017;61(4):1–16.spa
dc.relation.referencesYamauchi K, Tomita M, Giehl TJ, Ellison RT. Antibacterial activity of lactoferrin and a pepsin-derived lactoferrin peptide fragment. Infect Immun.1993;61(2):719–28.spa
dc.relation.referencesVorland LH, Ulvatne H, Andersen J, Haukland HH, Rekdal Ø, Svendsen JS, et al. Lactoferricin of bovine origin is more active than lactoferricins of human, murine and caprine origin. Scand J Infect Dis. 1998;30(5):513–7.spa
dc.relation.referencesSinha M, Kaushik S, Kaur P, Sharma S, Singh TP. Antimicrobial lactoferrin peptides: The hidden players in the protective function of a multifunctional protein. Int J Pept. 2013;2013(February 2015).spa
dc.relation.referencesSchibli DJ, Hwang PM, Vogel HJ. The structure of the antimicrobial active center of lactoferricin B bound to sodium dodecyl sulfate micelles. FEBS Lett. 1999;446(2–3):213–7.spa
dc.relation.referencesLeón-Calvijo MA, Leal-Castro AL, Almanzar-Reina GA, Rosas-Pérez JE, García-Castañeda JE, Rivera-Monroy ZJ. Antibacterial Activity of Synthetic Peptides Derived from Lactoferricin against Escherichia coli ATCC 25922 and Enterococcus faecalis ATCC 29212. Biomed Res Int. 2015 Mar;2015:1–8.spa
dc.relation.referencesHuertas N de J, Monroy ZJR, Medina RF, Castañeda JEG. Antimicrobial Activity of Truncated and Polyvalent Peptides Derived from the FKCRRQWQWRMKKGLA Sequence against Escherichia coli ATCC 25922 and Staphylococcus aureus ATCC 25923. Molecules. 2017;22(6).spa
dc.relation.referencesVargas Casanova Y, Rodríguez Guerra JA, Umaña Pérez YA, Leal Castro AL, Almanzar Reina G, García Castañeda JE, et al. Antibacterial Synthetic Peptides Derived from Bovine Lactoferricin Exhibit Cytotoxic Effect against MDA-MB- 468 and MDA-MB-231 Breast Cancer Cell Lines. Molecules. 2017;22(10):1–11.spa
dc.relation.referencesVargas-Casanova Y, Rodríguez-Mayor AV, Cardenas KJ, Leal-Castro AL, Muñoz-Molina LC, Fierro-Medina R, et al. Synergistic bactericide and antibiotic effects of dimeric, tetrameric, or palindromic peptides containing the RWQWR motif against Gram-positive and Gram-negative strains. RSC Adv. 2019;9(13):7239–45.spa
dc.relation.referencesAlby K, Miller MB. Mechanisms and Detection of Antimicrobial Resistance [Internet]. Fifth Edit. Principles and Practice of Pediatric Infectious Diseases. Elsevier Inc.; 2017. 1467-1478.e4 p. Available from: http://dx.doi.org/10.1016/B978-0-323-40181-4.00290-5spa
dc.relation.referencesTheuretzbacher U. Global antibacterial resistance: The never-ending story. J Glob Antimicrob Resist [Internet]. 2013;1(2):63–9. Available from: http://dx.doi.org/10.1016/j.jgar.2013.03.010spa
dc.relation.referencesGómez Rubio A. Consumo de antibióticos en el ámbito hospitalario en Colombia, primer semestre de 2019. Inst Nac Salud. 2019;1–16.spa
dc.relation.referencesAfacan NJ, Yeung ATY, Pena OM, Hancock REW. Therapeutic potential of host defense peptides in antibiotic-resistant infections. Curr Pharm Des [Internet]. 2012;18(6):807–19. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22236127spa
dc.relation.referencesGermán Alberto Téllez1, Jhon Carlos Castaño1. Péptidos antimicrobianos Antimicrobial peptides. 2010;14(1):55–67. Available from: www.ncbi.nlm.nih.gov/pubmedspa
dc.relation.referencesRana M, Chatterjee S, Kochhar S, Pereira BMJ. Antimicrobial Peptides: a New Dawn for Regulating Fertility and Reproductive Tract Infections. J Endocrinol Reprod [Internet]. 2006;2:88–95. Available from: http://srbce.org/journal12b/002.pdfspa
dc.relation.referencesBellamy W, Takase M, Wakabayashi H, Kawase K, Tomita M. Antibacterial spectrum of lactoferricin B, a potent bactericidal peptide derived from the N‐terminal region of bovine lactoferrin. J Appl Bacteriol. 1992;73(6):472–9.spa
dc.relation.referencesSchiffer M, Chang CH, Stevens FJ. The functions of tryptophan residues in membrane proteins. Protein Eng Des Sel. 1992;5(3):213–4.spa
dc.relation.referencesDe Jesus AJ, Allen TW. The role of tryptophan side chains in membrane protein anchoring and hydrophobic mismatch. Biochim Biophys Acta - Biomembr [Internet]. 2013;1828(2):864–76. Available from: http://dx.doi.org/10.1016/j.bbamem.2012.09.009spa
dc.relation.referencesVorland LH, Osbakk SA, Perstølen T, Ulvatne H, Rekdal Ø, Svendsen JS, et al. Interference of the antimicrobial peptide lactoferricin B with the action of various antibiotics against Escherichia coli and Staphylococcus aureus. Scand J Infect Dis. 1999;31(2):173–7.spa
dc.relation.referencesFeng X jun, Wang J hua, Shan A shan, Teng D, Yang Y lin, Yao Y, et al. Fusion expression of bovine lactoferricin in Escherichia coli. Protein Expr Purif. 2006;47(1):110–7.spa
dc.relation.referencesVargas Casanova Y. Evaluación De La Actividad Antibacteriana De Péptidos Diméricos Y Tetraméricos Derivados De Lactoferricina Bovina Contra Bacterias Gram Positivas Y Gram Negativas. Universidad Nacional de Colombia; 2018.spa
dc.relation.referencesHuertas Méndez NDJ, Vargas Casanova Y, Gómez Chimbi AK, Hernández E, Leal Castro AL, Melo Diaz JM, et al. Synthetic Peptides Derived from Bovine Lactoferricin Exhibit Antimicrobial Activity against E. coli ATCC 11775, S. maltophilia ATCC 13636 and S. enteritidis ATCC 13076. Molecules. 2017;22(3):1–10.spa
dc.relation.referencesSinha M, Kaushik S, Kaur P, Sharma S, Singh TP. Antimicrobial lactoferrin peptides: The hidden players in the protective function of a multifunctional protein. Int J Pept. 2013;2013.spa
dc.relation.referencesGifford JL, Hunter HN, Vogel HJ. Lactoferricin: A lactoferrin-derived peptide with antimicrobial, antiviral, antitumor and immunological properties. CellMol Life Sci. 2005;62(22):2588–98.spa
dc.relation.referencesPtaszyńska N, Olkiewicz K, Okońska J, Gucwa K, Łęgowska A, Gitlin-Domagalska A, et al. Peptide conjugates of lactoferricin analogues and antimicrobials—Design, chemical synthesis, and evaluation of antimicrobial activity and mammalian cytotoxicity. Peptides [Internet]. 2019;117(March):170079. Available from: https://doi.org/10.1016/j.peptides.2019.04.006spa
dc.relation.referencesFarnaud S, Spiller C, Moriarty LC, Patel A, Gant V, Odell EW, et al. Interactions of lactoferricin-derived peptides with LPS and antimicrobial activity. FEMS Microbiol Lett. 2004;233(2):193–9.spa
dc.relation.referencesVega SC, Martínez DA, Chalá M del S, Vargas HA, Rosas JE. Design, synthesis and evaluation of branched RRWQWR-based peptides as antibacterial agents against clinically relevant gram-positive and gram-negative pathogens. Front Microbiol. 2018;9(MAR).spa
dc.relation.referencesVega Chaparro SC, Valencia Salguero JT, Martínez Baquero DA, Rosas Pérez JE. Effect of Polyvalence on the Antibacterial Activity of a Synthetic Peptide Derived from Bovine Lactoferricin against Healthcare-Associated Infectious Pathogens. Biomed Res Int. 2018;2018.spa
dc.relation.referencesConcepción Porrero Calonge. Detección y caracterización de Staphylococcus aureus procedentes de aninales y aguas. Universidad Complutense de Madrid; 2014.spa
dc.relation.referencesBorraz Ordás C. Epidemiología De La Resistencia a Meticilina [Internet].Universidad de barcelona; 2003. Available from: http://www.tdx.cat/bitstream/handle/10803/2513/CBO_TESIS_DOCTORAL.pdfspa
dc.relation.referencesDavies J, Davies D. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev. 2010;74(3):417–33.spa
dc.relation.referencesLeal-Castro AL, Álvarez CA. Resultados de la vigilancia de la resistencia bacteriana. 2019.spa
dc.relation.referencesLacueva Arnedo M. Resistencia a antibióticos en Staphylococcus aureus. Evolución y perspectiva actual [Internet]. Universidad complutense; 2017. Available from: https://eprints.ucm.es/54765/spa
dc.relation.referencesZhang HZ, Hackbarth CJ, Chansky KM, Chambers HF. A proteolytic transmembrane signaling pathway and resistance to β-lactams in staphylococci. Science (80- ). 2001;291(5510):1962–5.spa
dc.relation.referencesShajari G, Khorshidi A, Moosavi G. Vancomycin resistance in Staphylococcus aureus strains. Arch Razi Inst. 2017;90(54):107–10.spa
dc.relation.referencesAraos R, García P, Chanqueo L, Labarca J. Daptomycin: Pharmacological characteristics and its role in the treatment of gram positive infections. Rev Chil Infectología. 2012;29(2):127–31.spa
dc.relation.referencesCasanova, Natalia Gómez, María, Siller Ruiz JLMB. Mechanisms of resistance to Daptomycin in Staphylococcus aureus. Kasmera [Internet]. 2010;38(6):36–44. Available from: http://seq.es/wp- content/uploads/2017/12/gomez25oct2017.pdfspa
dc.relation.referencesVelasco C de caceres. Evolución de la resistencia a antibióticos en Staphylococcus aureus . Universidad Complutense; 2016.spa
dc.relation.referencesRuiz Larrea F, Lantero M, Torres Gómez C, Portillo A, Zarazaga Chamorro M, Olarte I, et al. Resistencia a antibióticos macrólidos-lincosamidas- estreptograminas y mecanismos implicados en cepas clínicas de “Streptococcus” spp. en La Rioja. Zubía. 2000;12(12):11–26.spa
dc.relation.referencesMcCallum N, Berger-Bächi B, Senn MM. Regulation of antibiotic resistance in Staphylococcus aureus. Int J Med Microbiol. 2010;300(2–3):118–29.spa
dc.relation.referencesBenito Pascual D. Líneas genéticas, virulencia y resistencia a antibióticos en Staphylococcus aureus de diferentes orígenes. Análisis de marcadores de adaptación al huésped y comportamiento en Caenorhabditis elegans. Universidad de la Rioja; 2015.spa
dc.relation.referencesTruong-Bolduc QC, Dunman PM, Strahilevitz J, Projan SJ, Hooper DC. MgrA is a multiple regulator of two new efflux pumps in Staphylococcus aureus. J Bacteriol. 2005;187(7):2395–405.spa
dc.relation.referencesRomeu B. Caracterización de cepas de Escherichia coli de importancia clínica humana aisladas de ecosistemas dulceacuícolas de La Habana. Repositorio de Tesis Universidad de La Habana. 2012.spa
dc.relation.referencesGrupo de evaluación de riesgos de inocuidad de Alimentos. Perfil de riesgo de Escherichia coli enterotoxigénica y verotoxigénica en queso fresco [Internet]. Instituto Nacional de Salud. 2015. Available from: http://www.ghbook.ir/index.php?name option=com_dbook&task=readonline&book_id=13650&page=73&chkha&نوین shk=ED9C9491B4&Itemid=218&lang=fa&tmpl=componentspa
dc.relation.referencesAlonso CA. Epidemiología molecular en Escherichia coli procedente de fauna salvaje : resistencia antimicrobiana , virulencia y diversidad y diversidad genética. Universidad de la Rioja; 2018.spa
dc.relation.referencesVargas CRS. Elaboración y evaluación del material didáctico variedades enterovirulentas de Escherichia coli [Internet]. UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO; 2014. Available from: https://www.zaragoza.unam.mx/portal/wp- content/Portal2015/Licenciaturas/qfb/tesis/tesis_salas_vargas.pdfspa
dc.relation.referencesGales AC, Castanheira M, Jones RN, Sader HS. Antimicrobial resistance among Gram-negative bacilli isolated from Latin America: Results from SENTRY Antimicrobial Surveillance Program (Latin America, 2008-2010). Diagn Microbiol Infect Dis [Internet]. 2012;73(4):354–60. Available from: http://dx.doi.org/10.1016/j.diagmicrobio.2012.04.007spa
dc.relation.referencesGarcía-Hernández AM, García-Vázquez E, Hernández-Torres A, Ruiz J, Yagüe G, Herrero JA, et al. Bacteraemia due to Escherichia coli producing extended-spectrum beta-lactamases (ESBL): clinical relevance and today’s insights. Rev Esp Quimioter [Internet]. 2011;24(2):57–66. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21666996spa
dc.relation.referencesRice LB. Mechanisms of resistance and clinical relevance of resistance to β- lactams, glycopeptides, and fluoroquinolones. Mayo Clin Proc [Internet]. 2012;87(2):198–208. Available from: http://dx.doi.org/10.1016/j.mayocp.2011.12.003spa
dc.relation.referencesSerra A. QUINOLONAS. Separata. 2008;16.spa
dc.relation.referencesMunita JM, Arias CA. Mechanisms of Antibiotic Resistance. Annu Rep Med Chem. 2016;4(2):119–27.spa
dc.relation.referencesGrünbaum F. Resistencia a aminoglucósidos en ENTEROBACTERIACEAE [Internet]. Universidad autónoma de Barcelona; 2011. Available from: http://www.tdx.cat/bitstream/handle/10803/42291/fg1de1.pdf?sequence=1spa
dc.relation.referencesMaldonado N, Robledo C, Robledo J. La espectrometría de masas MALDI-TOF en el laboratorio de microbiología clínica. Infectio. 2018;22(1):35–45.spa
dc.relation.referencesDemirev P, Sandrin T. Aplications of mass spectrometry in microbiology. New York: Springer Cham Heidelberg; 2016. 1–336 p.spa
dc.relation.referencesSampedro A, Ceballos Mendiola J, Aliaga Martínez L. MALDI-TOF Commercial Platforms for Bacterial Identification [Internet]. The Use of Mass Spectrometry Technology (MALDI-TOF) in Clinical Microbiology. Elsevier Inc.; 2018. 47–57 p. Available from: http://dx.doi.org/10.1016/B978-0-12- 814451-0.00003-4spa
dc.relation.referencesCramer R. Advances in MALDI and laser-induced soft ionization mass spectrometry. Adv MALDI Laser-Induced Soft Ioniz Mass Spectrom. 2015;1– 286.spa
dc.relation.referencesCLSI. M100 Performance Standards for Antimicrobial Susceptibility Testing [Internet]. Vol. 8, Journal of Services Marketing. 2019. 27–39 p. Available from: http://www.emeraldinsight.com/doi/10.1108/08876049410065598spa
dc.relation.referencesWiegand I, Hilpert K, Hancock REW. Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat Protoc. 2008;3(2):163–75.spa
dc.relation.referencesDoern CD. When does 2 plus 2 equal 5? A review of antimicrobial synergy testing. J Clin Microbiol. 2014;52(12):4124–8.spa
dc.relation.referencesVargas-Casanova Y. EVALUACIÓN DE LA ACTIVIDAD ANTIBACTERIANA DE PÉPTIDOS DIMÉRICOS Y TETRAMÉRICOS DERIVADOS DE LACTOFERRICINA BOVINA CONTRA BACTERIAS GRAM POSITIVAS Y GRAM NEGATIVAS. Universidad nacional de Colombia; 2018.spa
dc.relation.referencesToledo MRF, Trabulsi LR. Correlation between biochemical and serological characteristics of Escherichia coli and results of the Sereny test. J Clin Microbiol. 1983;17(3):419–21.spa
dc.relation.referencesPark JJ, Seo Y Bin, Lee J. Antimicrobial susceptibilities of Enterobacteriaceae in community-acquired urinary tract infections during a 5-year period: A single hospital study in Korea. Infect Chemother. 2017;49(3):184–93.spa
dc.relation.referencesCeballos-Garzón A, Cabrera E, Cortes-Fraile GC, León A, Aguirre-Guataqui K, Linares-Linares MY, et al. In-house protocol and performance of MALDI- TOF MS in the early diagnosis of bloodstream infections in a fourth-level hospital in Colombia: Jumping to full use of this technology. Int J Infect Dis. 2020;101:85–9.spa
dc.relation.referencesBhat G, Bhat G. Atypical Escherichia Coli in Urinary Tract Infection. Trop Doct. 1995;25(3):127.spa
dc.relation.referencesRaksha R, Srinivasa H, Macaden RS. Occurrence and characterisation of Uropathogenic Escherichia coli in urinary tract infections. Indian J Med Microbiol [Internet]. 2003;21(2):102–7. Available from: https://doi.org/10.1016/S0255-0857(21)03130-3spa
dc.relation.referencesT. R, M J. Prevalence of Atypical E . coli Causing Urinary Tract Infection in a Tertiary Care Hospital . Australas Med J. 2010;3(8):545–6.spa
dc.relation.referencesBajpai T, Pandey M, Varma M, Bhatambare G. Importance of identification of lactose nonfermenting Escherichia coli and their prevalence in urinary isolates. CHRISMED J Heal Res. 2016;3(4):288.spa
dc.relation.referencesKaczmarek A, Skowron K, Budzyńska A, Grudlewska K, Gospodarek- Komkowska E. Virulence genes and antimicrobial susceptibility of lactose- negative and lactose-positive strains of Escherichia coli isolated from pregnant women and neonates. Folia Microbiol (Praha). 2017;62(5):363–71.spa
dc.relation.referencesChang J, Yu J, Lee H, Ryu H, Park K, Park YJ. Prevalence and characteristics of lactose non-fermenting Escherichia coli in urinary isolates. J Infect Chemother [Internet]. 2014;20(11):738–40. Available from: http://dx.doi.org/10.1016/j.jiac.2014.07.005spa
dc.relation.referencesHrabák J, Chudác ̌ková E, Walková R. Matrix-assisted laser desorption ionization-time of flight (MALDITOF) mass spectrometry for detection of antibiotic resistance mechanisms: From research to routine diagnosis. Clin Microbiol Rev. 2013;26(1):103–14.spa
dc.relation.referencesCeballos-Garzon A, Amado D, Vélez N, Jiménez-A MJ, Rodríguez C, Parra- Giraldo CM. Development and validation of an in-house library of colombian candida auris strains with maldi-TOF MS to improve yeast identification. J Fungi. 2020;6(2):1–8.spa
dc.relation.referencesSanguinetti M, Posteraro B. Mass spectrometry applications in microbiology beyond microbe identification: progress and potential. Expert Rev Proteomics. 2016;13(10):965–77.spa
dc.relation.referencesKallow W, Erhard M, Shah H, Raptakis E, Welker M. MALDI - TOF MS for Microbial Identifi cation : Years of Experimental Development to an. In: Shah H, Gharbia S, editors. Mass Spectrometry for Microbial Proteomics. London; 2010. p. 255–76. 88. Dingle TC, Butler-Wu SM. MALDI-TOF mass spectrometry for microorganism identification. Clin Lab Med. 2013;33(3):589–609.spa
dc.relation.referencesGil Gonzalo A. Espectrometría MALDI‐TOF aplicada a levaduras enológicas: identificación. [Internet]. Universidad de Valladolid; 2014. Available from: http://uvadoc.uva.es/bitstream/handle/10324/38124/TFG- G3567.pdf?sequence=1.spa
dc.relation.referencesCipolla L, Rocca F, Armitano RI, Martinez C, Almuzara M, Faccone D, et al. Development and evaluation of an in-house database for quick identification of Burkholderia contaminans by MALDI-TOF MS. Rev Argent Microbiol [Internet]. 2019;51(3):255–8. Available from: https://doi.org/10.1016/j.ram.2018.09.001spa
dc.relation.referencesBou G, Fernández-Olmos A, García C, Sáez-Nieto JA, Valdezate S. Métodos de identificación bacteriana en el laboratorio de microbiología. Enferm Infecc Microbiol Clin. 2011;29(8):601–8.spa
dc.relation.referencesLeón-Calvijo MA, Leal-Castro AL, Almanzar-Reina GA, Rosas-Pérez JE, García-Castañeda JE, Rivera-Monroy ZJ. Antibacterial Activity of Synthetic Peptides Derived from Lactoferricin against Escherichia coli ATCC 25922 and Enterococcus faecalis ATCC 29212 . Biomed Res Int. 2015;2015:1–8.spa
dc.relation.referencesFlores-Villaseñor H, Canizalez-Román A, Reyes-Lopez M, Nazmi K, De La Garza M, Zazueta-Beltrán J, et al. Bactericidal effect of bovine lactoferrin, LFcin, LFampin and LFchimera on antibiotic-resistant Staphylococcus aureus and Escherichia coli. BioMetals. 2010;23(3):569–78.spa
dc.relation.referencesPane K, Durante L, Crescenzi O, Cafaro V, Pizzo E, Varcamonti M, et al. Antimicrobial potency of cationic antimicrobial peptides can be predicted from their amino acid composition: Application to the detection of “cryptic” antimicrobial peptides. J Theor Biol [Internet]. 2017;419(January):254–65. Available from: http://dx.doi.org/10.1016/j.jtbi.2017.02.012spa
dc.relation.referencesYau WM, Wimley WC, Gawrisch K, White SH. The preference of tryptophan for membrane interfaces. Biochemistry. 1998;37(42):14713–8.spa
dc.relation.referencesSun H, Greathouse D V., Andersen OS, Koeppe RE. The preference of tryptophan for membrane interfaces: Insights from N-methylation of tryptophans in gramicidin channels. J Biol Chem. 2008;283(32):22233–43.spa
dc.relation.referencesWimley WC, White SH. Membrane Partitioning: Distinguishing Bilayer Effects from the Hydrophobic Effect. Biochemistry. 1993;32(25):6307–12.spa
dc.relation.referencesChan DI, Prenner EJ, Vogel HJ. Tryptophan- and arginine-rich antimicrobial peptides: Structures and mechanisms of action. Biochim Biophys Acta - Biomembr. 2006;1758(9):1184–202.spa
dc.relation.referencesHaukland HH, Ulvatne H, Sandvik K, Vorland LH. The antimicrobial peptides lactoferricin B and magainin 2 cross over the bacterial cytoplasmic membrane and reside in the cytoplasm. FEBS Lett. 2001;508(3):389–93.spa
dc.relation.referencesVergis J, Malik SS, Pathak R, Kumar M, Ramanjaneya S, Kurkure NV, et al. Exploiting Lactoferricin (17–30) as a Potential Antimicrobial and Antibiofilm Candidate Against Multi-Drug-Resistant Enteroaggregative Escherichia coli. Front Microbiol. 2020;11(September):1–13.spa
dc.relation.referencesBonapace CR, Bosso JA, Friedrich L V., White RL. Comparison of methods of interpretation of checkerboard synergy testing. Diagn Microbiol Infect Dis. 2002;44(4):363–6.spa
dc.rightsDerechos reservados al autor, 2021spa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.licenseReconocimiento 4.0 Internacionalspa
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/spa
dc.subject.ddc610 - Medicina y salud::615 - Farmacología y terapéuticaspa
dc.subject.decsAntibacterianos
dc.subject.decsAnti-Bacterial Agents
dc.subject.decsEnfermedades transmisibles
dc.subject.decsCommunicable Diseases
dc.subject.proposalLactoferricina Bovinaspa
dc.subject.proposalActividad antibacterianaspa
dc.subject.proposalAislados clínicosspa
dc.subject.proposalMultirresistentesspa
dc.subject.proposalPéptidos antimicrobianosspa
dc.subject.proposalBovine lactoferricineng
dc.subject.proposalAntibacterial activityeng
dc.subject.proposalClinical isolateseng
dc.subject.proposalAntimicrobial peptideseng
dc.titleActividad antibacteriana del péptido LfcinB (20-25)4 contra aislados clínicos multirresistentes de E. coli Y S. aureusspa
dc.title.translatedAntibacterial activity of the LfcinB (20-25) 4 peptide against multi-resistant clinical isolates of E. coli and S. aureuseng
dc.typeTrabajo de grado - Maestríaspa
dc.type.coarhttp://purl.org/coar/resource_type/c_bdccspa
dc.type.coarversionhttp://purl.org/coar/version/c_ab4af688f83e57aaspa
dc.type.contentTextspa
dc.type.driverinfo:eu-repo/semantics/masterThesisspa
dc.type.redcolhttp://purl.org/redcol/resource_type/TMspa
dc.type.versioninfo:eu-repo/semantics/acceptedVersionspa
dcterms.audienceEspecializadaspa
oaire.accessrightshttp://purl.org/coar/access_right/c_abf2spa
oaire.awardtitleDiseño y obtención de nuevos agentes antibacterianos basados en dendrímero péptido – resorcinareno: Una alternativa para combatir la resistencia bacteriana.spa
oaire.fundernameMINCIENCIAS (COLCIENCIAS)spa

Archivos

Bloque original

Mostrando 1 - 1 de 1
Miniatura
Nombre:
1032464031.2021.pdf
Tamaño:
1.64 MB
Formato:
Adobe Portable Document Format
Descripción:
Tesis de Maestría en Ciencias - Microbiología
Descargar

Bloque de licencias

Mostrando 1 - 1 de 1
Miniatura
Nombre:
license.txt
Tamaño:
3.87 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Maestría en Ciencias - Microbiología